β-Thalassemias are a group of hereditary blood disorders characterized by abnormalities in the synthesis of the β hemoglobin (Hb) chains. This disease causes excessive storage of iron in all organs and endocrine glands. Treatment of β-thalassemia major (β-TM) consists of regular blood transfusions, iron chelation and management of secondary complications of iron overload. Endocrine abnormalities are frequently observed. In the last 25 years, the clinical picture of the disease has changed progressively thanks to improvement of treatments. Today, the majority of thalassemic patients reach adult age. The better prognosis and the longer lifespan of affected patients could be responsible for the susceptibility to other concomitant diseases which can manifest during their life. In this context, the possibility and recent literature reports about some cases of malignancy in thalassemic patients open new scenarios for oncoming years. We describe first reports of endocrine malignancies in thalassemic patients.

Download full-text PDF

Source
http://dx.doi.org/10.3109/03630269.2011.588355DOI Listing

Publication Analysis

Top Keywords

thalassemic patients
12
patients
5
malignancies β-thalassemia
4
β-thalassemia patients
4
patients description
4
description cases
4
cases thyroid
4
thyroid cancer
4
cancer review
4
review literature
4

Similar Publications

Background: Thalassemia is one of the most common congenital hemoglobinopathies globally. Regular red blood cell (RBC) transfusion is of paramount importance in the treatment of thalassemia patients. However, this practice increases the risk of alloimmunization.

View Article and Find Full Text PDF

Thalassemia is an inherited hematological disorder characterized by a decrease in the synthesis of or absence of one or more globin chains. Hepatitis E virus (HEV) is a major cause of acute viral hepatitis, constituting a major global health burden and emerging as a critical public health concern. HEV infection is mainly transmitted via the fecal-oral route; however, parenteral transmission through blood components has been reported in both developing and developed countries.

View Article and Find Full Text PDF

Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.

J Endocrinol Invest

January 2025

Section of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Aim: This review aims to overview factors contributing to TAO development and addresses the targeted diagnostic work-up and treatment management in adult thalassemic patients.

Results: Osteoporosis management in Thalassemia is challenging because several factors contributing to its pathogenesis should be considered and controlled starting from child- hood. A multidisciplinary approach is crucial.

View Article and Find Full Text PDF
Article Synopsis
  • Thalassemia, particularly beta-thalassemia major, is a hereditary anemia marked by insufficient beta-globin chain production, leading to iron overload from frequent blood transfusions, with significant health complications like endocrinopathies.
  • The study focused on children aged 6 months to 14 years, examining growth and endocrine function in relation to serum ferritin levels, which indicate iron overload.
  • Results revealed a high prevalence of endocrinopathy, with short stature being the most commonly observed issue, particularly among boys and younger children.
View Article and Find Full Text PDF

Purpose: There is paucity of guidelines with inadequate data available about the extent and prevention of bone and joint disease in beta-thalassemic patients in Indian population. This study aims to determine bone and joint involvement in beta-thalassemic patients. It evaluates serum biochemical parameters of bone formation and resorption and correlates with the symptomatology in these patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!